Skip to main content
Clinical Trials/NCT04984213
NCT04984213CompletedNot Applicable

CORTI-FIX: Clinical and Radiographic Outcomes Following Lumbar Interbody Placement With Posterior Minimally Invasive Intra-Laminar PEEK Ratcheting Fixation Device

Spinal Elements1 site in 1 country20 target enrollmentStarted: August 15, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
20
Locations
1
Primary Endpoint
Fusion Rate

Study Overview

Brief Summary

The primary objective of this clinical study is to measure fusion rate in patients at 12 months following lumbar fusion in combination with posterior fixation using the Karma® device.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Skeletally mature and age ≥ 18 years of age
  • Appropriate patient as determined by the Investigator for anterior or lateral approach to lumbar interbody fusion surgery with planned posterior fixation to treat degenerative disc disease in one or two adjacent vertebral levels between L2 and S
  • Failed at least six months of conservative treatment. This may or may not include any of the following,
  • Spinal injections
  • Chiropractic care
  • Physical therapy
  • Activity modification and/or with anti-inflammatory medications
  • Oswestry Low Back Pain Disability Questionnaire score of at least 30%
  • Visual Analog Scale (VAS) for back/hip/lower extremity pain ranking at a minimum at least 3/10 (30%)
  • Psychosocially, mentally and physically able to fully comply with this protocol including adhering to follow-up schedule, study requirements with a signed informed consent with a study collaborator present at the time of signing to ensure compliance.

Exclusion Criteria

  • Patients with greater than two levels of degenerative disease or deformity for INTENDED operative levels.
  • Previous fusion or total disc replacement at the intended level/s
  • Known allergy to implant and instrument materials
  • Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma
  • Degenerative spondylolisthesis of grade >2
  • Isthmic spondylolisthesis
  • Back or leg pain of unknown etiology
  • Active systemic infection or infection at the location planned surgery
  • Active or suspected malignancy. If symptom free for 2 years, patients with prior malignancy may be included.
  • Morbid obesity defined as a body mass index > 40
  • Patient being treated for other specific medical conditions that may affect bone density or the ability to obtain fusion (ie: steroids, etc)
  • Pregnant or have plans to become pregnant in the next year.
  • Currently a prisoner
  • Patient has any condition, that in the opinion of the Investigator, would prohibit the patient from complying with the protocol
  • Participation in a concurrent clinical study.

Outcomes

Primary Outcomes

Fusion Rate

Time Frame: 12 months

Interbody Fusion Rate

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Study of the Long-Term Outcomes of... | Clinical Trial